title: Combined heart and lung transplantation for unresectable primary cardiac sarcoma.
abstract: OBJECTIVE
  The prognosis for patients with primary cardiac sarcoma is poor. Median survival is less than 10 months, especially when complete surgical excision is not feasible. Removal of all cardiopulmonary structures involved by tumor followed by orthotopic allotransplantation has been proposed to improve long-term survival.
  
  
  METHODS
  From 1996 through 1999, we performed combined heart and lung resection followed by en bloc heart and bilateral lung transplantation in 4 patients (2 men and 2 women): 2 with inoperable pulmonary arterial sarcoma and 2 with left atrial sarcoma extending into the pulmonary vein.
  
  
  RESULTS
  Median age at diagnosis was 39 years (range 37-45 years). All 4 patients were given chemotherapy before transplantation: doxorubicin and ifosfamide in 2 cases, and doxorubicin, ifosfamide, mesna, and dacarbazine in 2 cases. There were no operative deaths. Median survival after transplantation was 31 months (range 5-49 months). All patients had tumor recurrence: local recurrence in the chest (n = 1) and distant metastases in the brain (n = 2) and abdomen (n = 1). One patient remains alive 49 months after disease progression with cerebral metastasis as the only site of recurrence treated with whole-brain irradiation, resection, and stereotactic radiosurgery.
  
  
  CONCLUSIONS
  Combined heart and lung transplantation is a technically feasible treatment for highly selected patients with localized advanced primary cardiac sarcomas. The high incidence of metastatic disease, however, limits its utility.
authors.affiliation: Departments of Medicine and Surgery, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA.
authors.forename: Susan M
authors.initials: SM
authors.lastname: Talbot
authors.forename: Robert N
authors.initials: RN
authors.lastname: Taub
authors.forename: Mary Lou
authors.initials: ML
authors.lastname: Keohan
authors.forename: Niloo
authors.initials: N
authors.lastname: Edwards
authors.forename: Mark E
authors.initials: ME
authors.lastname: Galantowicz
authors.forename: Larry L
authors.initials: LL
authors.lastname: Schulman
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006338:Heart Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D016041:Heart-Lung Transplantation; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D011651:Pulmonary Artery; D012509:Sarcoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D019043:Vascular Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents